[
  {
    "ts": null,
    "headline": "Halozyme Therapeutics: The Waters Become Muddled",
    "summary": "Halozyme navigates CMS pricing risks impacting 2028+ revenues, yet strong royalties, FY25 guidance, and margins support stable near-term earnings.",
    "url": "https://finnhub.io/api/news?id=0eb822c739bc2c6b6e2f9bd66e19b34754e600f484cf108b0175ab34f6bf9cec",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749974539,
      "headline": "Halozyme Therapeutics: The Waters Become Muddled",
      "id": 135284784,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2203542103/image_2203542103.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Halozyme navigates CMS pricing risks impacting 2028+ revenues, yet strong royalties, FY25 guidance, and margins support stable near-term earnings.",
      "url": "https://finnhub.io/api/news?id=0eb822c739bc2c6b6e2f9bd66e19b34754e600f484cf108b0175ab34f6bf9cec"
    }
  }
]